Published in Lab Law Weekly, June 1st, 2007
During the quarter, PLIVA reported total revenue of HRK 1,924m compared to HRK 1,736m in 2006, with total sales of HRK 1,880m, up 14% from HRK 1,656m the previous year. Double digit growth performances recorded in markets such as the United States, United Kingdom, Slovenia, Czech Republic and Ukraine more than offset the approximately HRK 200m decline in azithromycin and royalty revenues.
Net Income was HRK 374m. Overall profitability was significantly positively impacted by intragroup...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.